DE60138558D1 - Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung - Google Patents

Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung

Info

Publication number
DE60138558D1
DE60138558D1 DE60138558T DE60138558T DE60138558D1 DE 60138558 D1 DE60138558 D1 DE 60138558D1 DE 60138558 T DE60138558 T DE 60138558T DE 60138558 T DE60138558 T DE 60138558T DE 60138558 D1 DE60138558 D1 DE 60138558D1
Authority
DE
Germany
Prior art keywords
peptide
paces
cell activity
present
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138558T
Other languages
English (en)
Inventor
Gabriele Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multimmune GmbH
Original Assignee
Multimmune GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multimmune GmbH filed Critical Multimmune GmbH
Application granted granted Critical
Publication of DE60138558D1 publication Critical patent/DE60138558D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
DE60138558T 2000-09-13 2001-09-13 Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung Expired - Lifetime DE60138558D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00119933 2000-09-13
PCT/EP2001/010593 WO2002022656A2 (en) 2000-09-13 2001-09-13 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
BE2009/0695A BE1019732A4 (fr) 2000-09-13 2009-11-12 Peptide de hsp70 simulant l'activite de cellules tueuses naturelles (nk) et ses utilisations.

Publications (1)

Publication Number Publication Date
DE60138558D1 true DE60138558D1 (de) 2009-06-10

Family

ID=47436345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138558T Expired - Lifetime DE60138558D1 (de) 2000-09-13 2001-09-13 Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung

Country Status (8)

Country Link
US (2) US7517948B2 (de)
EP (1) EP1319023B8 (de)
AT (1) ATE430161T1 (de)
AU (1) AU2002212236A1 (de)
BE (1) BE1019732A4 (de)
DE (1) DE60138558D1 (de)
ES (1) ES2326114T3 (de)
WO (1) WO2002022656A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517948B2 (en) * 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof
IL148401A0 (en) * 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
SI1537204T1 (sl) * 2002-08-23 2010-06-30 Gabriele Prof Dr Multhoff Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah
JP4898452B2 (ja) * 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体
WO2005054868A1 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
JP2010509257A (ja) * 2006-11-14 2010-03-25 ゲオルグ−アウグスト−ウニヴェルズテート ゲッティンゲン シュティフトゥング オッフェントリヒェン レヒツ 免疫療法のための組成物および方法
GB0705626D0 (en) * 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
ES2532083T3 (es) 2008-06-26 2015-03-24 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
WO2012023631A1 (ja) * 2010-08-19 2012-02-23 株式会社Eci ヒートショックプロテイン（ｈｓｐ）とｅｃｉ３０１ポリペプチドを含む癌細胞の増殖を抑制するための医薬組成物ならびにそれを用いた癌の治療方法
CN103338784A (zh) 2010-11-30 2013-10-02 奥菲泽米有限公司 用于增加Hsp70细胞内活性的方法
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
JP6678676B2 (ja) 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
RU2732925C2 (ru) 2015-01-26 2020-09-24 Селлектис МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК
TWI738646B (zh) 2015-04-07 2021-09-11 日商賽多利克公司 醫藥組成物
MX2018010961A (es) * 2016-03-10 2019-03-28 Aperisys Inc Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada.
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
WO2017186919A1 (en) 2016-04-29 2017-11-02 Orphazyme Aps Arimoclomol for treating glucocerebrosidase associated disorders
EP3504224A1 (de) * 2016-08-23 2019-07-03 Aimvion A/S Neuartige immunstimulierende peptide
CN106317216B (zh) * 2016-09-21 2019-07-19 南京农业大学 一种促进h9n2禽流感疫苗免疫效果的活性肽及应用
EP3527216B1 (de) 2016-10-11 2024-02-14 NEC Corporation Arzneimittel, das einen toll-like-rezeptor-agonist, lag-3-protein, ein derivat des hsp70 peptids und ein derivat des gpc3 peptids
EP3675877A1 (de) * 2017-08-31 2020-07-08 Multimmune GmbH Hsp70-basierte kombinationstherapie
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and its intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein
WO1999049881A2 (de) * 1998-03-27 1999-10-07 Gabriele Multhoff Verwendung von hsp70 protein
CN1057363C (zh) 1998-07-10 2000-10-11 贺德新 一种液压挤扩装置
JP4892132B2 (ja) * 1998-11-24 2012-03-07 ブリストル−マイヤーズ スクイブ カンパニー ７０ｋＤ熱ショック蛋白による化合物の細胞内標的輸送
US7517948B2 (en) * 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof

Also Published As

Publication number Publication date
US7745399B2 (en) 2010-06-29
US20090239802A1 (en) 2009-09-24
EP1319023A2 (de) 2003-06-18
ATE430161T1 (de) 2009-05-15
US20040063173A1 (en) 2004-04-01
BE1019732A4 (fr) 2012-12-04
EP1319023B1 (de) 2009-04-29
EP1319023B8 (de) 2009-07-15
US7517948B2 (en) 2009-04-14
ES2326114T3 (es) 2009-10-01
AU2002212236A1 (en) 2002-03-26
WO2002022656A2 (en) 2002-03-21
WO2002022656A3 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
WO2003064449A3 (en) Bioactive keratin peptides
WO2002044320A3 (en) Human elongase genes and uses thereof
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
ATE338121T1 (de) Von muc-1 abgeleitete peptide
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
EP1350848A3 (de) T-Zell-Membranprotein (TIRC7), dafür kodierendes Gen und Antikörper dagegen und ihre Verwendungen
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
DE60118359D1 (de) Humanische pellino-polypeptide
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
EP1812035A4 (de) Peptid mit antitumoraler wirkung
ATE373091T1 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
UA84831C2 (ru) Производные фактора коагуляции vii
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
CY1109617T1 (el) Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου
ATE338063T1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MULTIMMUNE GMBH C/O STRAHLENTHERAPIE DER TU MU, DE

8327 Change in the person/name/address of the patent owner

Owner name: MULTIMMUNE GMBH, 80634 MUENCHEN, DE

8364 No opposition during term of opposition